Overview

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.

Status:
Unknown status

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is: - To identify the common factor for L5 prevalence in patients with Metabolic Syndrome. - To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- promoting factor and reduce L5 in Metabolic Syndrome patients.

Phase:

Phase 4

Details

Lead Sponsor:

Baylor College of Medicine

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Ezetimibe
Ezetimibe, Simvastatin Drug Combination
Simvastatin